EP1682580A2 - Anticorps monoclonal humain reducteur de graisse - Google Patents

Anticorps monoclonal humain reducteur de graisse

Info

Publication number
EP1682580A2
EP1682580A2 EP04802719A EP04802719A EP1682580A2 EP 1682580 A2 EP1682580 A2 EP 1682580A2 EP 04802719 A EP04802719 A EP 04802719A EP 04802719 A EP04802719 A EP 04802719A EP 1682580 A2 EP1682580 A2 EP 1682580A2
Authority
EP
European Patent Office
Prior art keywords
seq
polypeptide
ldl
polypeptide according
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP04802719A
Other languages
German (de)
English (en)
Other versions
EP1682580B1 (fr
Inventor
Heinz Vollmers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Patrys Ltd
Original Assignee
Patrys Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Patrys Ltd filed Critical Patrys Ltd
Priority to EP10194202A priority Critical patent/EP2374820A3/fr
Publication of EP1682580A2 publication Critical patent/EP1682580A2/fr
Application granted granted Critical
Publication of EP1682580B1 publication Critical patent/EP1682580B1/fr
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Definitions

  • the invention relates to a purified polypeptide (SAM-6.10) and its use in combination with conventional auxiliaries and / or
  • Thrombus formation Atherosclerosis with its complications (coronary heart disease, heart attack, peripheral arterial disease, stroke) is still the most common cause of death in the western world. It is estimated that well over half of all financial resources available for medical care are spent on the consequences of arteriosclerosis. In order to clarify the causes of arteriosclerosis, various theories have been developed, the lipid theory being the most respected.
  • Fats such as B. cholesterol
  • Fats are neither soluble in water nor in blood fluid.
  • the fats are bound to certain protein bodies (proteins) as soon as they are in the blood.
  • proteins proteins
  • lipoproteins of the plasma are high-molecular water-soluble complexes, which consist of lipids (cholesterol, triglycerides, phospholipids) and apolipoproteins.
  • lipids cholesterol, triglycerides, phospholipids
  • apolipoproteins The lipoprotein LDL-cholesterol containing cholesterol causes arteriosclerosis and also becomes "bad".
  • Cholesterol called, the oxidized form of LDL cholesterol is even more dangerous for the body.
  • Crystalesterol is ubiquitously synthesized in the body and is an essential component of cell membranes and lipoproteins
  • the sterol ring of the cholesterol molecule can no longer be broken down; Cholesterol is converted to bile acid in the liver or excreted unchanged in the intestine via the bile.
  • LDL low-density lipoproteins
  • Triglycerides are esters of glycerol with three fatty acid residues. Analogous to cholesterol, the triglycerides are also transported in plasma bound to apolipoproteins due to their poor solubility.
  • Lipoproteins are synthesized in the liver or intestines and transport fat-soluble substances in the blood, such as cholesterol.
  • the lipoproteins are classified according to their density; a distinction is made between the five density classes: chylomicrons, very low density lipoproteines (VDL), low density lipoproteines (LDL) and high density lipoproteines (HDL).
  • VDL very low density lipoproteines
  • LDL low density lipoproteines
  • HDL high density lipoproteines
  • the chylomicrons whose physiological concentration in the fasting serum is very low in contrast to that of the other lipoproteins, are transport vehicles for exogenous glycerides.
  • the physiological distribution of the other lipoproteins is as follows: VLDL 0%, LDL 70% and HDL 20%.
  • VLDL are the forerunners of LDL and vehicles for the transport of endogenous glycerides.
  • LDL are created by the hydrolysis of the VLDL.
  • LDL and HDL are both regulators of cellular cholesterol homeostasis, with HDL also regulating lipolysis (cleavage of triglycerides into glycerin and free fatty acids).
  • LDL have a diameter of approx. 20 nm.
  • HDL are the smallest (7-10 nm) and protein richest lipoproteins.
  • oxidized LDL (oxLDL) can also be detected in the blood serum.
  • oxLDL interacts with endogenous plasma proteins, especially glycoproteins, through specific ligands and forms oxLDL-glycoprotein complexes.
  • Apolipoproteins are a component of the lipoproteins and, together with polar lipids, surround the lipoprotein core made of hydrophobic lipids as a kind of outer shell. With the exception of LDL, which only contains apoprotein B, the individual lipoprotein classes have several structurally different ones Apolipoprotein classes.
  • Cholesterol is mainly transported by the two lipoprotein classes LDL and HDL. LDL are primarily responsible for the
  • LDL cholesterol increases in connection with HDL cholesterol reductions represent the most pronounced risk increase for arteriosclerosis.
  • LDL whose particles contribute significantly to the formation of atherosclerotic plaques, and HDL therefore play an opposite role in pathogenesis.
  • the quotients of total cholesterol / HDL cholesterol and in particular LDL cholesterol / HDL cholesterol are decisive for assessing the risk of infarction.
  • oxLDL-glycoprotein complexes To play role.
  • concentration of oxLDL-glycoprotein complexes is higher in patients with chronic kidney failure and diabetes than in healthy patients.
  • LDL is removed from the bloodstream by the liver and macrophages.
  • Macrophages are cells of the foreign body defense system that are capable of phagocytosis of larger particles.
  • the "scavenger pathway” is a well-known model for explaining the uptake of particles by cells (phagocytosis).
  • phagocytosis The uptake of solid particles (tissue debris, foreign bodies, bacteria or LDL plaques) into the cell interior of phagocytes with subsequent intracellular degradation takes place by phagocytosis.
  • the cells capable of phagocytosis are also referred to as phagocytes and consist mainly of tissue macrophages and mobile ones
  • phagocytosis after the particles have been attached to the cell membranes of the phagocytes, by binding to membrane-bound Fc and complement receptors, contractile structures within the cytoplasm are activated. Local indentations of the cell membranes result in the particles being enclosed in cytoplasmic vacuoles.
  • the so-called clearing (scavenger) phagocytes can be found in the lymph nodes in and along the fiber strands belonging to the medulla (marrow). During the lymphatic passage from the afferent to the efferent end of the lymph node, particulate antigens are removed by the cells capable of phagocytosis.
  • Cells such as polymorphonuclear leukocytes and macrophages, are enlarged by the attachment of immunoglobulins (Ig) to the surface of bacteria (and other antigens). It is believed that the increased adherence is caused by the attachment of the Fc portion of the immunoglobulin to the Fc receptors of the phagocytes.
  • Ig immunoglobulins
  • the complex of antigen and antibodies is absorbed and digested more quickly by the phagocytic cells.
  • the coating of the antibody surface with immunoglobulins is also referred to as opsonin-related (Fc) adherence and plays an important role in immune defense.
  • the antibodies that bind to the surface of bacterial cells are able to fix certain components of the extracellular fluids.
  • these components are referred to as "complement”.
  • Animal experiments have shown that the phagocytosis of cells coated with antibodies is delayed in those animals with a complement deficiency. It therefore suggests that there is a synergism between antibodies and complement during opsonization. Description of the invention
  • the effect of the drugs known from the prior art for lowering LDL cholesterol is based on the inhibition of the key enzyme in cholesterol synthesis (CSE).
  • the cholesterol synthesis inhibitor is, for example, one under the trade name
  • CSE inhibitors in general are significant and include gastrointestinal disorders, sleep disorders, dizziness, visual disturbances, allergic reactions and hair loss. Only in the experimental stage, and only in the case of severe familial hypercholesterolemia, is an approach of somatic gene therapy which involves the transfer of the gene for the LDL receptor to autologous liver cells.
  • a substance that is largely free of side effects and acts as a fat reducer is not yet on the market.
  • antibodies which induce an increased intracellular accumulation of lipoproteins have so far not been known.
  • the damaging role of lipoproteins in kidney diseases lipid-induced damage to cells of the glomerulus filtration apparatus of the kidney
  • the object of the invention is to generate a new substance or a new class of substances for the manufacture of a medicament for reducing LDL cholesterol or oxLDL cholesterol in humans and animals with the advantageous aim of reducing the risk of infarction.
  • a polypeptide is proposed, the amino acid sequence of which is essentially identical to the amino acid sequence of SEQ ID NO: 1 and / or SEQ ID NO: 3, and the low density lipoproteins (LDL) and / or oxidized LDL ( oxLDL), in particular LDL cholesterol and / or oxidized LDL cholesterol (oxLDL cholesterol) binds.
  • the essence of the invention consists in the surprising observation that a purified polypeptide, the sequence of which corresponds in whole or in part to the light (V L ) or heavy chain (VH) of a human monoclonal antibody (SAM-6.10), reduces the low density lipoproteins (LDL) and / or oxLDLs causes.
  • V L light
  • VH heavy chain
  • SAM-6.10 human monoclonal antibody
  • the antibody according to the invention comprises the groups V L , V H , Fv, FC, Fab, Fab ', F (ab') 2 designated according to the common nomenclature for describing antibodies.
  • the groups mentioned are also referred to as fragments. It is entirely possible that a single fragment is the cause of the fat-lowering effect of the polypeptide according to the invention.
  • it is a human monoclonal antibody.
  • a “functional fragment” in the sense of the invention is a polypeptide that has at least one of the biological activities that also the entire polypeptide has.
  • the specific binding of the antibody can be accomplished, for example, by only one CD region, even though there are a total of 3 CD regions.
  • the specific binding of the antibody to an antigen can be used, for example, to induce apoptosis or to inhibit the
  • the biological activity of a functional fragment can be measured by various methods known to the person skilled in the art
  • CDRs complementartity-determining regions of the polypeptide sequence contain the amino acid sequence which is essentially identical to the amino acid sequence Ser-Gly-Asp-Lys-Leu-Gly-Asp-Lys-Tyr-Ala-Cys (CDR1), GIn -Asp-Ser-Lys-Arg-Pro-Ser (CDR2) and Gln-Ala-TrpAsp-Ser-Ser-lle-Val-Val (CDR3) of SEQ ID NO 1 of the light chain variable region (V L ); see also Figure 2.
  • CDRs complementarity-determining regions of the peptide sequence contain amino acid sequences which are essentially identical to Ser-Tyr-Ala-Met-His (CDR1), Val-Ile-Ser-Tyr-Asp-Gly-Ser-Asn-Lys- Tyr-Tyr-Ala-Asp-Ser-Val-Lys-Gly (CDR2) and Asp-Arg-Leu-Ala-Val-Ala-Gly-Lys-Thr-Phe-Asp-Tyr (CDR3) of SEQ ID NO 3 the variable region light chain (VH); see also Figure 4.
  • a “substantially identical” is a polypeptide or a nucleic acid sequence that is at least 75%, 80%, 85%, or 90% with the amino acid sequence given as a reference (SEQ ID NO:
  • polypeptides In a further development of the polypeptide or the nucleic acid sequence, at least 95%, 98%, 99% or 100% identity can be demonstrated in comparison to the references given.
  • the length of the comparison section will generally be at least 5, 10, 15 or desirably at least 20 or 25 consecutive amino acids.
  • polypeptide according to the invention can be generated by a process which is known under the name Hypridoma technique (Köhler, Millstein,
  • kidney diseases in particular glomerulonecrosis (glomerulosclerosis).
  • the polypeptide according to the invention is preferably used in the purified form for the production of the medicament, all methods known to the person skilled in the art (e.g. affinity chromatography, gel filtration) being suitable for purification.
  • all methods known to the person skilled in the art e.g. affinity chromatography, gel filtration
  • the focus is on the fat-lowering effect, in particular the selective lowering of LDL or LDL cholesterol. Due to the property of LDL and / or oxLDL to bind more than
  • HDL causes the polypeptide according to the invention to have a low value for the quotient from LDL / HDL and / or oxLDL / HDL and thus minimizes the risk of infarction.
  • auxiliaries and excipients for the production of a pharmaceutical are known to the person skilled in the art and can be produced according to common practice (see Remington: The Science and Practice of Pharmacy (20 th ed.), Ed. AR Gennaro, Lippincott Williams & Wilkins, 2000 and Encyclopedia of Pharmaceutical Technology, eds. J. Swarbrick and JC Boylan, 1988-1999, Marcel Dekker, New York).
  • lymphocytes are fused and cultivated with the heteromyeloma HAB-1 (Faller et al., 1990) according to the standard protocol. Briefly summarized, lymphocytes are fused with HAB-1 cells using PEG. The trioms are sown on four 24-hole plates. The average growth frequency is 80-90%, 50% of the growing clones secrete immunoglobulins.
  • the secreted human monoclonal antibodies are tested for the first time in an ELISA to determine the isotype. The human monoclonal antibodies can subsequently be analyzed immunohistochemically, genetically, biochemically and molecular biologically.
  • RPMI 1640 (company PAA) without additives RPMI 1640 with HAT addition (HAT supplement, company PAA) as well as 10% FCS, 1% glutamine and 1% penicillin / streptomycin HAB-1 (fusion partner) twice with RPMI without additives wash centrifuge thaw frozen lymphocytes (from spleen, lymph nodes or blood) for 5 min at 1500 rpm and wash twice with RPMI without additives, likewise centrifuge both pellets each in 10 ml RPMI without additive and count in a ratio of 1 in the Neubauer counting chamber : 2 - 1: 3, Hab-1 to lymphocytes, fuse the cell pellets together after the second washing process, mix and centrifuge for 8 min at 1500 rpm, the PEG (Polyethylene Glycol 1500, Röche), previously warmed at 37 ° C, carefully Let it drip onto the pellet while rotating the 50 ml tube gently, then resuspend gently and then exactly 90 seconds. then rotate in a water bath at 37 ° C,
  • HAT hypoxanthine, aminopterin, thymidine
  • the hybridoma cells producing the IgM antibody SAM-6.10 were used for this purpose in a special serum-free cell culture medium (AIMV medium, Gibco) and the IgM content in the culture supernatant was determined nephelometrically.
  • AIMV medium serum-free cell culture medium
  • the culture supernatant was adjusted to a pH of 5.9 and the solution was filtered.
  • a special cation column HiTrap TM SP FF column, 5 ml, Amersham Bioscience was used for binding. The column was equilibrated with filtered buffer A (20 mM phosphate buffer, pH 5.9) at the beginning of the purification.
  • the column was washed with buffer A for 20 min and a flow rate of 2 ml / min to a baseline constant in order to remove all unbound proteins.
  • the antibody bound to the column was then eluted by admixing buffer B (20 mM phosphate buffer, 1 M NaCl, pH 8.0) and collected in fractions.
  • the content of SAM-6.10 antibody (IgM) in the individual fractions was determined nephelometrically below and the purity and
  • the measurement is carried out using the Oxidized LDL ELISA test kit from Mercodia, Uppsala, Sweden.
  • Test principle The ELISA for oxidized LDL is an enzymatic, bilateral immunoassay with a solid phase. It is based on the direct sandwich technique, in which two monoclonal antibodies against a specific antigen are aligned on oxidized apolipoprotein B. During the incubation, oxidized LDL in the sample reacts with anti-oxidized LDL antibodies, which are bound to the wells in the microtiter plate.
  • a peroxidase-conjugated anti-human apolipoprotein B antibody recognizes the oxidized LDL bound to the solid phase. After a second incubation and a washing process which removes the antibodies labeled with the unbound enzyme, the conjugate is reacted with
  • TMB 5'-tetramethylbenzidine
  • Trypsin / EDTA detached from the bottom of the culture bottles.
  • the reaction was stopped with 10 ml of RPMI-1640 medium (+ supplements) and the cells were pelleted at 1000 ⁇ g for 5 min.
  • the cells were washed twice with PBS, taken up in FACS buffer (PBS, 0.01% Na azide) and placed on ice for 30 min to reconstitute the cell membranes.
  • the cells were then adjusted to a density of 1 ⁇ 10 6 cells / ml and each 200 ⁇ l of the cell suspensions were transferred to FACS reaction vessels, so that there was a cell count of 2 ⁇ 10 5 cells per tube.
  • the cells were pelleted for 5 min at 4 ° C.
  • the pellets resuspended and incubated with the primary antibodies on ice for 15 min.
  • 100 ⁇ g / ml SAM-6 antibodies in FACS buffer (total volume 200 ⁇ l) or 100 mg / ml LDL were used as primary antibodies.
  • 100 ⁇ g / ml Chrompure human IgM acted as an isotype control.
  • the cells were pre-incubated with LDL for 30 min and then for 15 min
  • F ITC-coupled secondary antibody (Rabbit anti human IgM, F ITC-coupled, 1:50 in FACS buffer for SAM-6 or Chrompure human IgM). After another wash, the cells were taken up in 200 ⁇ l cold FACS buffer and kept on ice until protected from light until measurement. The measurement was carried out using a
  • Experiment 1 500 ⁇ g of purified SAM-6.10 antibody was injected intra peritoneally. The LDL concentration in the blood serum was checked
  • Experiment 3 1 mg of purified SAM-6.10 antibodies were injected intraperitoneally. The LDL concentration in the blood serum was measured after 14 days.
  • Control A normal values for control mouse
  • Control B normal values for control mouse
  • the serum concentration of LDL is significantly reduced in the mice treated with SAM-6.10 (see FIGS. 10 and 11).
  • liver, lungs, heart, spleen, small intestine, colon, kidneys, stomach and brain showed no morphological changes.
  • organs were immunohistochemically examined for possible lipid deposits. examined. Staining with Sudan III showed no lipid storage in any organ.
  • the organs of the killed mice were fixed in formalin and embedded in paraffin.
  • the dyeing was carried out using the Sudan III dye according to the following protocol:
  • the adherent macrophages are grown on object supports and then treated with the appropriate agents.
  • the staining is carried out as follows: Fixation of the cells in 60% isopropanol (6 min) • Incubate 20 minutes with Sudan III
  • the measurement of the different lipids in the blood serum was carried out automatically with the MODULAR D P800 device (Röche).
  • the LDL cholesterol value was determined using an enzymatic, colorimetric method (CHOD / PAP) without sample pretreatment.
  • HDL, VLDL and chylomicrons are specifically hydrolyzed by a detergent 1.
  • the cholesterol released in these lipoproteins reacts immediately through the enzymatic action of cholesterol esterase (CE) and cholesterol oxidase (CHOD) and hydrogen peroxide is formed.
  • CE cholesterol esterase
  • CHOD cholesterol oxidase
  • the LDL particles remain intact step by step.
  • the reaction of LDL cholesterol is triggered by adding detergent 2 and the coupling substance N, N-bis (4-sulfobutyl) -m-toluidine (DSBmT).
  • the second detergent releases cholesterol in the LDL particles.
  • a dye is formed in the enzymatic reaction in the presence of the coupling substance.
  • the intensity of the red quinonimine dye formed is directly proportional to the LDL cholesterol concentration. It is determined by measuring the increase in absorbance at 552 nm.
  • ELISA LDL / HDL
  • LDL Lipoprotein Low Density tyfrom Human Plasma, Sigma, 10 ⁇ g / ml in PBS
  • HDL Human HDL, Chemicon, 10 ⁇ g / ml in PBS
  • Figure 1 shows the amino acid sequences (SEQ ID NO 1) of the variable region of the light chain (VL).
  • Figure 2 shows the nucleotide acid sequence (SEQ ID NO 2) of the light chain variable region (VL).
  • the complementarity-determining regions (CDR) are marked by dashes and are essentially identical to nucleotides 67-99 (CDR1), 145-165
  • Figure 3 shows the amino acid sequences (SEQ ID NO 3) of the heavy chain variable region (VH).
  • Figure 4 shows the nucleotide acid sequence (SEQ ID NO 4) of the heavy chain variable region (VH).
  • the complementarity-determining regions (CDR) are identified by dashes and are essentially identical to nucleotides 91-105 (CDR1), 148-198 (CDR2) and 295-330 (CDR3) from SEQ ID NO 4.
  • FIG. 5 shows the measurement of oxLDL as a function of the incubation period with a copper sulfate solution.
  • LDL Sigma, Taufkirchen, Germany
  • ELISA determined the amount of oxi- dated LDL determined. It can be clearly seen that the amount of oxidized LDL increases with increasing incubation time, and even that LDL fraction that has not been treated with copper ions is partly already in oxidized form. After 15 hours of incubation, the proportion of oxidized LDL has approximately doubled.
  • FIG. 6 shows the detection of the binding of SAM-6 to oxLDL.
  • the ELISA plate was pre-coated with differently oxidized LDL fractions before the first antibody
  • Figure 7 shows the result of a FACS analysis.
  • the cells used for this are cells from the mouse macrophage cell line P388D1 (IL-1) (DSMZ Accession No. ACC 288).
  • Figure 7A shows the binding of LDL to macrophages.
  • FIG. 7B shows that the human monoclonal antibody SAM-6 also binds to macrophages.
  • FIG. 7C shows that the macrophages have ⁇ -receptors.
  • FIG. 7D With the right shift of the signal in FIG. 7D it is shown that a simultaneous incubation of LDL and SAM-6 brings about an increased binding of SAM-6 to the cells.
  • FIG. 8 shows cells which were incubated for 48 hours with either SAM-6 or an IgM control antibody and then subjected to Sudan III staining.
  • SAM-6 show a clear deposition of neutral fats due to the red color.
  • Those incubated with the control antibody show a clear deposition of neutral fats due to the red color.
  • FIG. 9 For the stains shown in FIG. 9, the macrophages were cultivated for 24 hours both with and without the addition of FCS. Thereafter, only LDL or only SAM-6 or LDL and SAM-6 were added together for a further 24 hours. A Sudan III staining was then carried out.
  • the left column of the image with FIGS. 9A, 9C and 9E show cells that were cultivated without the addition of FCS.
  • the right-hand image column with FIGS. 9B, 9D and 9F show cells which were cultivated with the addition of FCS.
  • FIGS. 9A and 9B show that both macrophages which have been cultivated without FCS and macrophages which have grown in the presence of FCS show a basal storage of neutral fats.
  • FIG. 9C shows that when
  • FIGS. 9E and 9F show that with a co-incubation of SAM-6 and LDL, the intracellular lipid accumulation increases markedly both in macrophages which have been cultured with FCS and in those which have grown without the addition of FCS.
  • FIG. 10 shows the influence of the antibody SAM-6 on LDL values in vivo.
  • the mice were given 1 mg of purified SAM-6 antibody per or in the control experiment 1 mg human Chrompure IgM (isotype control) ip injected.
  • the LDL concentration in the blood was measured after 24 and 48 hours. A clear reduction in serum LDL can be observed after 24 and 48 hours in mice treated with SAM-6.
  • FIG. 11 also demonstrates the in vivo effect of SAM-6.10, an indirect method using the Friedewald formula being used to calculate the values.
  • the amount of LDL is calculated from the difference between total cholesterol, HDL and triglycerides. According to this type of test evaluation, the reduction in the concentration of LDL in the serum after SAM-6.10 treatment would be even greater. However, this indirect measurement method must be regarded as less precise than the method used in FIG. 10.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne un polypeptide épuré, dont la séquence d'acide aminé est sensiblement identique à celle de SEQ ID N0:1 et de SEQ ID N0:3, ce polypeptide liant des lipoprotéines de faible densité (LDL) et/ou une LDL oxydée (oxLDL), notamment un cholestérol LDL et/ou un cholestérol LDL oxydé (cholestérol oxLDL). La présente invention porte également sur l'utilisation de ce polypeptide en combinaison avec des substances auxiliaires et/ou supports usuelles pour réaliser un médicament réducteur de graisse et des médicaments pour traiter des maladies rénales.
EP04802719.7A 2003-11-14 2004-11-12 Anticorps monoclonal humain reducteur de graisse Not-in-force EP1682580B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP10194202A EP2374820A3 (fr) 2003-11-14 2004-11-12 Anticorps monoclonal humain reducteur de graisse

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10353175A DE10353175A1 (de) 2003-11-14 2003-11-14 Humaner monoklonaler Antikörper mit fettsenkender Wirkung
PCT/DE2004/002503 WO2005049635A2 (fr) 2003-11-14 2004-11-12 Anticorps monoclonal humain reducteur de graisse

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP10194202.7 Division-Into 2010-12-08

Publications (2)

Publication Number Publication Date
EP1682580A2 true EP1682580A2 (fr) 2006-07-26
EP1682580B1 EP1682580B1 (fr) 2013-05-15

Family

ID=34585082

Family Applications (2)

Application Number Title Priority Date Filing Date
EP10194202A Withdrawn EP2374820A3 (fr) 2003-11-14 2004-11-12 Anticorps monoclonal humain reducteur de graisse
EP04802719.7A Not-in-force EP1682580B1 (fr) 2003-11-14 2004-11-12 Anticorps monoclonal humain reducteur de graisse

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP10194202A Withdrawn EP2374820A3 (fr) 2003-11-14 2004-11-12 Anticorps monoclonal humain reducteur de graisse

Country Status (6)

Country Link
US (2) US8124080B2 (fr)
EP (2) EP2374820A3 (fr)
JP (1) JP4980068B2 (fr)
DE (2) DE10353175A1 (fr)
ES (1) ES2424639T3 (fr)
WO (1) WO2005049635A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1531162A1 (fr) 2003-11-14 2005-05-18 Heinz Vollmers Anticorps SAM-6, spécifique d'adénocarcinome, et ses utilisations
ES2476798T3 (es) 2006-11-27 2014-07-15 Patrys Limited Nueva diana de p�ptido glucosilado en células neopl�sicas
WO2010088739A1 (fr) * 2009-02-09 2010-08-12 Patrys Limited Variants de sam-6, cible et procédés d'utilisation correspondants
GB201200563D0 (en) * 2012-01-13 2012-02-29 Imp Innovations Ltd Binding molecule
EP2789629A1 (fr) * 2013-04-11 2014-10-15 Universiteit Maastricht Procédé pour le traitement de maladies de stockage lipidiques lysozomales
JP7403241B2 (ja) * 2019-06-07 2023-12-22 小林製薬株式会社 内臓脂肪の視認性向上方法

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
US5126240A (en) * 1986-09-29 1992-06-30 Curtiss Linda K Hybridomas and monoclonal paratopic molecules to apolipoprotein a-i
ATE121197T1 (de) * 1988-01-19 1995-04-15 Pasteur Institut Immunometrisches verfahren zum nachweis von lipoprotein-teilchen, anti-lp(a) monoklonale antikörper und ihre anwendung zur diagnose von atherosklerose.
DE4107154A1 (de) 1990-10-11 1992-04-16 Boehringer Mannheim Gmbh Monoklonale antikoerper gegen melanom
AU662311B2 (en) 1991-02-05 1995-08-31 Novartis Ag Recombinant antibodies specific for a growth factor receptor
GB9105292D0 (en) 1991-03-13 1991-04-24 Sandoz Ltd Improvements in or relating to organic compounds
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5622701A (en) 1994-06-14 1997-04-22 Protein Design Labs, Inc. Cross-reacting monoclonal antibodies specific for E- and P-selectin
US5639863A (en) 1994-06-21 1997-06-17 Dan; Michael D. Human monoclonal antibodies specific to cell cycle independent glioma surface antigen
US6429289B1 (en) * 1994-06-23 2002-08-06 Massachusetts Institute Of Technology Class BI and CI scavenger receptors
GB9424449D0 (en) 1994-12-02 1995-01-18 Wellcome Found Antibodies
US6140470A (en) 1995-06-30 2000-10-31 Yale University Human monoclonal anti-tumor antibodies
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
AU4982097A (en) 1996-10-18 1998-05-15 Board Of Regents, The University Of Texas System Anti-erbb2 antibodies
EP0927757A1 (fr) 1997-12-03 1999-07-07 Leadd B.V. Méthodes et moyens pour induire l'apoptose par interférence avec des protéines similaires à Bip
CA2319089A1 (fr) 1998-04-09 1999-10-21 Genset S.A. Etiquettes de sequences exprimees (est) des 5' et proteines humaines codees
DK1087993T3 (da) 1998-06-18 2008-07-14 Imed Ab Fas-peptider og antistoffer til at modulere apoptose
DE69901569T2 (de) 1998-08-28 2002-12-19 Genentech Inc Humane antikörper gegen faktor ix/ixa
GB9822115D0 (en) 1998-10-09 1998-12-02 King S College London Treatment of inflammatory disease
PT1141019E (pt) 1998-12-22 2004-09-30 Heinz Peter Vollmers Fragmento da glicoproteina cd55/daf para a obtencao de medicamentos antitumorais com elevada eficacia assim como processo para a sua utilizacao
CN101066997B (zh) 1999-03-25 2013-03-27 艾博特股份有限两合公司 结合人il-12的人抗体及其生产方法
US7049132B1 (en) 1999-06-28 2006-05-23 University Of Southern California Stress-responsive induction of a therapeutic agent and methods of use
US6677442B1 (en) 1999-10-29 2004-01-13 University Of Kentucky Research Foundation Nucleic acid encoding human REV1 protein
MXPA02008144A (es) 2000-02-23 2002-11-29 Amgen Inc Agentes de enlace selectivos antagonistas de la proteina de enlace de osteoprotegerina.
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
ES2609016T3 (es) 2000-06-16 2017-04-18 Human Genome Sciences, Inc. Anticuerpos que se unen inmunoespecíficamente a BLyS
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US20030105003A1 (en) 2001-04-05 2003-06-05 Jan Nilsson Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
CA2443862A1 (fr) 2001-04-17 2002-10-24 Peizhi Luo Construction structurelle de bibiotheques d'anticorps humains
CN1558914A (zh) 2001-07-24 2004-12-29 ��˹�������¡�����-��÷���� 受体、其应用以及小鼠抗体
US7671010B2 (en) 2002-08-30 2010-03-02 The Board Of Regents Of The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
US20040048243A1 (en) 2001-09-07 2004-03-11 Wadih Arap Methods and compositions for in vitro targeting
ATE550352T1 (de) 2001-12-03 2012-04-15 Alexion Pharma Inc Verfahren zur herstellung von hybridantikörper
DE10210427A1 (de) 2002-03-09 2003-10-09 Hans Konrad Mueller-Hermelink Humaner monoklonaler Antikörper
EP1572079A4 (fr) * 2002-03-29 2006-09-06 Centocor Inc Corps mimetiques de cdr de mammifere, compositions, procedes et utilisations
EP2322559A3 (fr) 2002-07-04 2011-08-03 Patrys Limited Anticorps specifiques de neoplasme et utilisations associees
DE10230516A1 (de) 2002-07-06 2004-01-15 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper
AU2002364501A1 (en) 2002-08-30 2004-03-19 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
SE0302312D0 (sv) 2002-10-04 2003-08-27 Forskarpatent I Syd Ab Peptide-based passive immunization therapy for treatment of atherosclerosis
DE10311248A1 (de) 2003-03-14 2004-09-30 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper
WO2005001052A2 (fr) 2003-06-06 2005-01-06 University Of Massachusetts Modulation de l'apoptose
AU2004288166B2 (en) 2003-10-27 2008-12-18 University Of Southern California Methods and compositions for modulating apoptosis
NZ577824A (en) 2003-11-12 2010-10-29 Patrys Ltd Methods of identifying neoplasm-specific antibodies and uses thereof
EP1531162A1 (fr) 2003-11-14 2005-05-18 Heinz Vollmers Anticorps SAM-6, spécifique d'adénocarcinome, et ses utilisations
WO2005065418A2 (fr) 2003-12-31 2005-07-21 Board Of Regents, The University Of Texas System Compositions et procedes d'utilisation de peptides de ciblage pour le diagnostic et la therapie
GB0404936D0 (en) 2004-03-04 2004-04-07 Univ London Screen
DE102004015179A1 (de) 2004-03-25 2005-10-13 Oncomab Gmbh Antigen des PM-2 Antikörpers und dessen Verwendung
ES2476798T3 (es) 2006-11-27 2014-07-15 Patrys Limited Nueva diana de p�ptido glucosilado en células neopl�sicas
WO2009104100A2 (fr) * 2008-02-19 2009-08-27 Patrys Limited Combinaisons d’anticorps et leurs procédés de fabrication et d’utilisation
WO2010088739A1 (fr) 2009-02-09 2010-08-12 Patrys Limited Variants de sam-6, cible et procédés d'utilisation correspondants

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2005049635A2 *

Also Published As

Publication number Publication date
WO2005049635A2 (fr) 2005-06-02
DE10353175A1 (de) 2005-06-16
JP2007537995A (ja) 2007-12-27
US8124080B2 (en) 2012-02-28
US9273125B2 (en) 2016-03-01
US20080045701A1 (en) 2008-02-21
EP2374820A2 (fr) 2011-10-12
WO2005049635A3 (fr) 2006-02-02
JP4980068B2 (ja) 2012-07-18
EP1682580B1 (fr) 2013-05-15
EP2374820A3 (fr) 2012-01-11
ES2424639T3 (es) 2013-10-07
US20130072664A1 (en) 2013-03-21
DE112004002660D2 (de) 2006-10-05

Similar Documents

Publication Publication Date Title
DE60226036T3 (de) ANTIKÖRPER, DER DAS GM1-GANGLIOSID-GEBUNDENE AMYLOID-b-PROTEIN ERKENNT, UND DNA, DIE FÜR DIESEN ANTIKÖRPER CODIERT
DE69925909T2 (de) T-zell inhibierende rezeptorzusammensetzungen sowie deren verwendung
DE3439345C2 (de) Verwendung von hyperimmuner Milch zur Behandlung von Herzgefäßerkrankungen bei Tier und Mensch
DE69735294T2 (de) Spezifische monoklonale antikörper für die extrazelluläre domäne von protasta-spezifischem membranantigen
DE69333209T2 (de) Angiogenese-inhibierende antikörper
DE60018761T2 (de) Therapeutischer antikörper gegen das muc-1-antigen und verfahren zu dessen verwendung
EP0480440B1 (fr) Anticorps monoclonal contre le mélanome
DE69433563T2 (de) Gegen das ca55.1 antigen gerichtete bindende strukturen
DE60223688T2 (de) Verfahren zur behandlung von multiplem myelom
Morace et al. Renal globotriaosylceramide facilitates tubular albumin absorption and its inhibition protects against acute kidney injury
DE69911322T2 (de) Monoklonaler antikörper der die oligosaccharide sialinsäure n-glycolierte galactose-glucose auf bösartige tumoren erkennt und zusammensetzungen die dieser enthalten
US9273125B2 (en) Human monoclonal antibody having fat-reducing effect
DE60113976T2 (de) Funktionaler nachweis von lipoprotein mit hoher dichte
Kikuchi et al. Severe proteinuria, sustained for 6 months, induces tubular epithelial cell injury and cell infiltration in rats but not progressive interstitial fibrosis
EP2129403B1 (fr) Construction polypeptidique bispécifique au potentiel thérapeutique et diagnostique
DE10210427A1 (de) Humaner monoklonaler Antikörper
EP1747011A2 (fr) Agents et procedes pour le diagnostic, la prophylaxie et la therapie de maladies du tissu conjonctif
WO2007012449A1 (fr) Frizzled 9 en tant que marqueur tumoral
DE69233122T2 (de) Verfahren zur Herstellung von Hybridomen
JP2007537995A5 (fr)
DE4120213C2 (de) Monoklonale Antikörper gegen das TNF-bindende Protein I (TNF-BP I)
WO1992022666A1 (fr) Anticorps monoclonaux contre la proteine i de liaison du facteur de necrose tumorale humain (p i de liaison du tnf)
AT502227B1 (de) Verfahren zur diagnose von tumoren
EP0618815B1 (fr) Anticorps monoclonaux diriges contre la phospholipase a 2? de type i, utilises comme agent therapeutique inhibant l'inflammation
DE4103727A1 (de) Zur spezifischen erkennung eines antigens des stratum corneum der menschlichen epidermis befaehigte antikoerper, ihre herstellung und ihre anwendung, insbesondere als traeger von arzneimittelwirkstoffen

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060511

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL HR LT LV MK YU

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PATRYS LIMITED

RIN1 Information on inventor provided before grant (corrected)

Inventor name: PATRYS LIMITED

17Q First examination report despatched

Effective date: 20081202

RIN1 Information on inventor provided before grant (corrected)

Inventor name: VOLLMERS, H. PETER

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LU MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Free format text: NOT ENGLISH

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 612133

Country of ref document: AT

Kind code of ref document: T

Effective date: 20130615

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

Free format text: LANGUAGE OF EP DOCUMENT: GERMAN

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 502004014177

Country of ref document: DE

Effective date: 20130704

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2424639

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20131007

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20130515

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130915

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130515

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130515

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130816

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130515

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130916

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130815

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130515

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130515

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130515

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130515

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130515

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130515

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130515

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20140218

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 502004014177

Country of ref document: DE

Effective date: 20140218

BERE Be: lapsed

Owner name: PATRYS LTD

Effective date: 20131130

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20131130

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130515

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20131130

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20131130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20131112

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 612133

Country of ref document: AT

Kind code of ref document: T

Effective date: 20131112

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20131112

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130515

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130515

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20131112

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20041112

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20161122

Year of fee payment: 13

Ref country code: ES

Payment date: 20161028

Year of fee payment: 13

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 14

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171112

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20181204

Year of fee payment: 15

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171113

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20181128

Year of fee payment: 15

Ref country code: FR

Payment date: 20181129

Year of fee payment: 15

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 502004014177

Country of ref document: DE

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20191112

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191112

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191130

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200603